Search results for "Dopamine receptor D1"

showing 10 items of 13 documents

Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators.

2016

Abstract The dopamine-amino acid conjugate DA-Phen was firstly designed to obtain a useful prodrug for the therapy of Parkinson's disease, but experimental evidence shows that it effectively interacts with D1 dopamine receptors (D1DRs), leading to an enhancement in cognitive flexibility and to the development of adaptive strategies in aversive mazes, together with a decrease in despair-like behavior. In this paper, homology modelling, molecular dynamics, and site mapping of D1 receptor were carried out with the aim of further performing docking studies on other dopamine conjugates compared with D1 agonists, in the attempt to identify new compounds with potential dopaminergic activity. Two n…

0301 basic medicineDopamineDopamine AgentsChemistry Techniques SyntheticPharmacology01 natural sciencesDocking03 medical and health sciencesDopamine receptor D1Drug StabilityDopamineCatalytic DomainDrug DiscoverymedicineAnimalsHumansAmino Acidschemistry.chemical_classificationConjugatePharmacologyPCA010405 organic chemistryChemistrySynthesiDrug Discovery3003 Pharmaceutical ScienceReceptors Dopamine D1DopaminergicOrganic ChemistryBrainGeneral MedicineProdrug0104 chemical sciencesAmino acidAmino acidRatsMolecular Docking Simulation030104 developmental biologyBiochemistryDocking (molecular)Dopamine receptorDrug DesignMolecular modellingConjugatemedicine.drugEuropean journal of medicinal chemistry
researchProduct

Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection.

2017

Abstract Parkinson’s disease (PD) is characterized by a degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) that causes a dopamine (DA) deficit in the caudate-putamen (CPu) accompanied by compensatory changes in other neurotransmitter systems. These changes result in severe motor and non-motor symptoms. To disclose the role of various receptor binding sites for DA, noradrenaline, and serotonin in the hemiparkinsonian (hemi-PD) rat model induced by unilateral 6-hydroxydopamine (6-OHDA) injection, the densities of D1, D2/D3, α1, α2, and 5HT2A receptors were longitudinally visualized and measured in the CPu of hemi-PD rats by quantitative in vitro receptor autorad…

0301 basic medicineMalemedicine.medical_specialtyApomorphine5-HT2A receptorNeurotoxinsSubstantia nigraMotor ActivityFunctional LateralityAntiparkinson Agents03 medical and health sciences0302 clinical medicineDopamine receptor D1Parkinsonian DisordersDopamine receptor D3DopamineInternal medicinemedicineAnimalsddc:610Longitudinal StudiesBotulinum Toxins Type ARats WistarReceptorOxidopamine5-HT receptorChemistryGeneral NeuroscienceDopaminergicCorpus StriatumReceptors Neurotransmitter030104 developmental biologyEndocrinologyDopamine Agonists030217 neurology & neurosurgerymedicine.drugNeuroscience
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies.

2002

Adult Wistar rats injected with the dopamine receptor agonist apomorphine display different types of motility patterns with respect to oral stereotypes and locomotor activities. It was tested whether phenotypes exhibiting either ‘sniffing’ or ‘non-sniffing’ behaviour differed in gene structures of dopamine receptors D1 or D2. Forty-five Wistar rats of both genders were tested after a single dose of apomorphine (2 mg/kg s.c.) for stereotyped behaviour. Sequence analysis of the 5′ flanking region, the 5′ untranslated region and the coding region of the two genes revealed a new sequence for the 5′ flanking region of the D1 receptor gene and two polymorphisms in the promoter region of the D2 re…

AgonistMalemedicine.medical_specialtyApomorphineGenotypemedicine.drug_classDopamine AgentsMolecular Sequence DataStereotypic Movement DisorderPharmacologyBiologyRats Sprague-Dawley03 medical and health sciences0302 clinical medicineDopamine receptor D1SniffingInternal medicineStereotypyDopamine receptor D2medicineCoding regionAnimalsRats WistarMolecular Biology030304 developmental biology0303 health sciencesPolymorphism GeneticBase SequenceBehavior AnimalReceptors Dopamine D2General NeuroscienceReceptors Dopamine D1RatsApomorphineEndocrinologyPhenotypeDopamine receptorFemaleNeurology (clinical)medicine.symptom030217 neurology & neurosurgeryDevelopmental Biologymedicine.drugBrain research
researchProduct

Reduction of red-green discrimination by dopamine D1 receptor antagonists and retinal dopamine depletion

1996

AbstractReduction of wavelength discrimination ability in the 560–640 nm range, but not in the 404–540 nm range, has been demonstrated in goldfish after intravitreal injection of D1-dopamine receptor antagonists. Intravitreal injection of the dopaminergic neurotoxin 6-OH-dopamine severely reduced wavelength discrimination ability in the 540–661 nm range within 3 days. Discrimination ability could be reconstituted by the Dl-agonist SKF 38393. Animals recovered from injection of 6-OH-dopamine within 14–16 days. No change of wavelength discrimination was induced by 6-OH-dopamine in the 461–540 nm range. We conclude that under photopic conditions dopamine modulates retinal mechanisms involved i…

DopamineWavelength discriminationRetinaHydroxydopamineschemistry.chemical_compoundDiscrimination PsychologicalDopamine receptor D1OpticsDopamineGoldfishmedicineAnimalsNeurotoxinDopamine receptorsNeurotransmitterRetinabusiness.industryReceptors Dopamine D1DopaminergicRetinalSensory SystemsOphthalmologymedicine.anatomical_structurechemistryDopamine receptorDopamine AgonistsBiophysicssense organsbusinessColor Perceptionmedicine.drugVision Research
researchProduct

Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens

2008

The mu- and delta-opioid receptors located at the terminal level in nucleus accumbens are involved in the opiate modulation of dopamine release in this brain area. However, recent studies suggest that the effects of opioid drugs on the core subregion of nucleus accumbens may completely differ from those observed in the shell. We used in vivo microdialysis to simultaneously apply selective mu- and delta-opioid receptor agonists and to measure extracellular levels of dopamine in three subregions of the accumbens, namely shell, core, and the transition zone between them. The regional analysis of these subregions of the accumbens demonstrated that basal levels of dopamine and its metabolites we…

MaleAgonistTime FactorsEnkephalinmedicine.drug_classDopamineMicrodialysisReceptors Opioid muPharmacologyNucleus accumbensNucleus Accumbensδ-opioid receptorCellular and Molecular Neurosciencechemistry.chemical_compoundDopamine receptor D1DopamineReceptors Opioid deltamedicineAnimalsRats WistarPharmacologyDopaminergicHomovanillic AcidEnkephalin Ala(2)-MePhe(4)-Gly(5)-RatsAnalgesics OpioidDAMGOchemistry34-Dihydroxyphenylacetic AcidEnkephalin D-Penicillamine (25)-medicine.drugNeuropharmacology
researchProduct

Understanding Cannabinoid Psychoactivity with Mouse Genetic Models

2007

Marijuana and its main psychotropic ingredient Δ9-tetrahydrocannabinol (THC) exert a plethora of psychoactive effects through the activation of the neuronal cannabinoid receptor type 1 (CB1), which is expressed by different neuronal subpopulations in the central nervous system. The exact neuroanatomical substrates underlying each effect of THC are, however, not known. We tested locomotor, hypothermic, analgesic, and cataleptic effects of THC in conditional knockout mouse lines, which lack the expression of CB1 in different neuronal subpopulations, including principal brain neurons, GABAergic neurons (those that release γ aminobutyric acid), cortical glutamatergic neurons, and neurons expres…

MaleMESH: Body TemperatureCannabinoid receptormedicine.medical_treatmentGene ExpressionMESH: Receptor Cannabinoid CB1NeocortexMESH: gamma-Aminobutyric AcidMESH: CatalepsyPharmacologyHippocampusMESH: Mice KnockoutMESH: Corpus StriatumBody TemperatureMESH: Autonomic Nervous SystemMESH: NeocortexMice0302 clinical medicineReceptor Cannabinoid CB1MESH: Behavior AnimalCannabinoid receptor type 1MESH: AnimalsMESH: Gene SilencingDronabinolMESH: NociceptorsBiology (General)gamma-Aminobutyric AcidMice Knockout0303 health sciencesBehavior Animalmusculoskeletal neural and ocular physiologyGeneral NeuroscienceMESH: Pain ThresholdNociceptorsMESH: Glutamic AcidMESH: InterneuronsMESH: Motor Activity3. Good healthGABAergicMESH: TetrahydrocannabinolGeneral Agricultural and Biological SciencesResearch Articlemedicine.drugPain ThresholdMESH: Gene ExpressionMESH: Psychotropic DrugsQH301-705.5Glutamic AcidMotor ActivityBiologyAutonomic Nervous SystemGeneral Biochemistry Genetics and Molecular Biologygamma-Aminobutyric acid03 medical and health sciencesGlutamatergicDopamine receptor D1InterneuronsCannabinoid Receptor Modulatorsmental disorders[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsGenetic Predisposition to Disease[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyGene SilencingTetrahydrocannabinolMESH: MiceAnesthesiology and Pain Management030304 developmental biologyPharmacologyCatalepsyPsychotropic DrugsModels GeneticGeneral Immunology and MicrobiologyCannabinoidsIllicit Drugsorganic chemicalsMESH: MaleCorpus StriatumPrimerDisease Models Animalnervous systemCannabinoidNervous System Diseases030217 neurology & neurosurgeryNeurosciencePLoS Biology
researchProduct

Lunasin-induced behavioural effects in mice: Focus on the dopaminergic system

2013

The present study for the first time is devoted to identify central effects of synthetic lunasin, a 43 amino acid peptide. A markedly expressed neuroleptic/cataleptic effect was observed at low (0.1-10 nmol/mouse) centrally administered doses in male C57Bl/6 mice. Lunasin considerably reduced the amphetamine hyperlocomotion but weakly apomorphine climbing behaviour. No influence on ketamine and bicuculline effects was observed. Binding assay studies demonstrated modest affinity of lunasin for the dopamine D₁ receptor (Ki=60 ± 15 μM). In a functional assay of cAMP accumulation on live cells lunasin antagonised apomorphine effect on D₁ receptor activation (pEC₅₀=6.1 ± 0.3), but had no effect …

Malemedicine.medical_specialtyApomorphineDopamine AgentsMotor ActivityPharmacologyBicucullineLunasinBehavioral NeuroscienceDopamine receptor D1SeizuresDopamineInternal medicineCyclic AMPmedicineAnimalsHumansGABA-A Receptor AntagonistsAmphetamineReceptorCatalepsyReceptors Dopamine D2ChemistryReceptors Dopamine D1DopaminergicBrainMice Inbred C57BLApomorphineAmphetamineHEK293 CellsEndocrinologyDopamine receptorSoybean ProteinsKetamineExcitatory Amino Acid AntagonistsCentral Nervous System Agentsmedicine.drugBehavioural Brain Research
researchProduct

Effects of two selective dopaminergic antagonists on ethologically-assessed encounters in male mice

1993

Abstract 1. Although it is accepted that dopaminergic antagonists suppress aggressive behaviour, the drugs used have been relatively non-selective or specific to the D2 receptor. 2. The selective D1 antagonist, SCH 23390, makes it possible to evaluate the impact of this receptor on aggressive behaviour. 3. The effects of SCH 23390 and Spiperone (a D2 antagonist) on the aggressive behaviour of mice were assessed employing a “standard opponent” test. 4. Both drugs markedly decreased aggressive behaviour whilst increasing immobility. However, whilst SCH 23390 increased immobility to a small extent, Spiperone, produced a general decline in active behaviours. 5. It appears that the D1 receptor i…

Malemedicine.medical_specialtySpiperoneMotor ActivityPharmacologyReceptors DopamineMicechemistry.chemical_compoundDopamine receptor D1Internal medicineDopamine receptor D2medicineAnimalsReceptorPharmacologySCH-23390business.industryAggressionAntagonistDopamine antagonistBenzazepinesAggressionEndocrinologychemistrySpiperonemedicine.symptombusinessmedicine.drugGeneral Pharmacology: The Vascular System
researchProduct

Dopamine D2 receptors mediate the increase in reinstatement of the conditioned rewarding effects of cocaine induced by acute social defeat

2017

Social stress modifies the activity of brain areas involved in the rewarding effects of psychostimulants, inducing neuroadaptations in the dopaminergic mesolimbic system and modifying the sensitivity of dopamine receptors. In the present study we evaluated the effect of the dopamine D1- and D2-like receptor antagonists (SCH23390 and raclopride, respectively) on the short-time effects of acute social defeat (ASD). Male OF1 mice were socially defeated before each conditioning session of the conditioned place preference (CPP) induced by 1mg/kg or 25mg/kg of cocaine plus the corresponding dopamine antagonist. A final experiment was designed to evaluate the effect of the dopamine antagonists on …

PharmacologyRaclopridebusiness.industryDopaminergicDopamine antagonistPharmacologyConditioned place preference030227 psychiatry03 medical and health sciences0302 clinical medicineDopamine receptor D1Dopamine receptorDopamineDopamine receptor D2AnesthesiaMedicinebusiness030217 neurology & neurosurgerymedicine.drugEuropean Journal of Pharmacology
researchProduct